Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Adverum Biotechnologies (NASDAQ:ADVM) with a $60 price target.
May 15, 2024 | 6:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee maintains a Buy rating on Adverum Biotechnologies with a $60 price target.
The reaffirmation of a Buy rating and a $60 price target by Truist Securities is a positive signal for investors, likely boosting short-term investor confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100